An Open-Label, Non-Inferiority Study Evaluating the Efficacy and Safety of Two Injection Schedules of Xeomin (incobotulinumtoxinA) [Short Flex Versus Long Flex] in Subjects With Cervical Dystonia With < 10 Weeks of Benefit From OnabotulinumtoxinA Treatment.
Phase of Trial: Phase IV
Latest Information Update: 11 Dec 2017
At a glance
- Drugs Botulinum toxin A (Primary)
- Indications Torticollis
- Focus Therapeutic Use
- Sponsors Merz Pharma
- 28 Mar 2017 Status changed from active, no longer recruiting to completed.
- 01 Jul 2016 Planned End Date changed from 1 Dec 2016 to 1 Sep 2017.
- 01 Jul 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Jul 2016.